Policy & Regulation
Hemogenyx partners with Lithuanian cancer centre on HG-CT-1 research and clinical programme
29 July 2026 - Biopharmaceutical group Hemogenyx Pharmaceuticals plc (LSE: HEMO) reported on Wednesday that it has signed a letter of intent with the National Cancer Centre at Vilnius University Hospi...
Evinova and Merck KGaA partner to accelerate AI-driven clinical development
29 July 2026 - Health-tech company Evinova said on Wednesday that it has entered into a multi-year strategic collaboration with German science and technology company Merck KGaA (ETR:MRK) to accelerate...
WuXi Biologics gains FTSE4Good recognition for sixth consecutive year
29 July 2026 - WuXi Biologics (HK:2269), a China-based global Contract Research, Development, and Manufacturing Organisation (CRDMO), announced on Tuesday that it has been included in the FTSE4Good In...
Lantern Pharma advances EMA-cleared Phase 1b/2 bladder cancer trial for LP-184
28 July 2026 - Clinical-stage, AI-native biopharma company Lantern Pharma Inc (NASDAQ:LTRN) said on Tuesday that the European Medicines Agency (EMA) has cleared an investigator-initiated Phase 1b/2 cl...
DifGen Pharmaceuticals' single injection treatment for advanced breast cancer cleared for clinical development
28 July 2026 - Generic pharmaceuticals manufacturer DifGen Pharmaceuticals LLC announced on Monday that the US Food and Drug Administration (FDA) has accepted the company's Investigational New Dr...
AbelZeta's C-CAR168 registrational Phase II trial in refractory Lupus Nephritis granted FDA clearance
28 July 2026 - Clinical-stage biopharmaceutical company AbelZeta Pharma Inc announced on Monday the receipt of US Food and Drug Administration (FDA) clearance under its Regenerative Medicine Advanced ...